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ABSTRACT
The intrusion of airborne allergens into airways elicits
eosinophilic inflammation, as represented by bronchial
asthma. It has been shown that excessive amounts of
allergen in murine trachea lead to an unexpected
evasion of deleterious eosinophilic inflammation by
inducing T cell tolerance. In the present study, the
mechanisms of tracheal high-dose tolerance are
examined with regard to accessory cell functions and
the effects of pro-inflammatory cytokines on tolerance.
Antigen-induced tracheal eosinophilia was suppressed
on instillation of high doses of antigen into the
trachea, while concurrent instillation of granulocyte–
macrophage colony stimulating factor (GM-CSF) with
the antigen restored the diminished responses. The
restoration of eosinophilic infiltration by GM-CSF
occurred in parallel with an increase in interleukin 
(IL)-4 production by CD4+ T cells from the mediastinal
lymph nodes. This was found to reflect the empower-
ment of antigen-presenting cells by GM-CSF, because
the impaired ability of Ia+ cells from the tolerant mice
to stimulate IL-4-producing T cells is restored by 
GM-CSF administration. The prevention of tolerance
by up-regulating accessory cell functions is a feature
unique to GM-CSF, because another pro-inflammatory
cytokine, IL-1b , failed to empower antigen-presenting
cells. Thus, besides the induction of transforming
growth factor-b -secreting CD4+ T cells, high-dose 
tolerance in the trachea includes an impairment of the
accessory cell functions that support IL-4 production
from T cells, which was reversed by GM-CSF. This
report is the first demonstration that GM-CSF breaks
the T cell tolerance of IL-4-producing T helper cells.
Key words: bronchial asthma, eosinophilia, T cell 
tolerance.
INTRODUCTION
The respiratory tract, a representative site of mucosal
tissue, is repeatedly exposed to a broad array of airborne
foreign allergens.1 Inhalation of allergens evokes deleteri-
ous immune and inflammatory responses in the airway,
as in bronchial asthma.2 The characteristic features of
bronchial asthma include airway eosinophilia and ele-
vated serum IgE levels, both of which are reported to be
orchestrated by T helper (Th)2 cells.3–9 The suppression of
Th2-dominated immune responses in this setting could
be a potential target of immunotherapy for bronchial
asthma.
Several distinct experimental approaches have been
taken to control airway eosinophilia by manipulating Th2
functions. For example, another CD4+ T cell subset, the
Th1 cells, exerts inhibitory effects on Th2 cells through 
the secretion of cytokines, such as g -interferon (IFN-g ).10
This subset is likely to be induced on infection with 
intracytoplasmic pathogens11–17 and exposure to Myco-
bacterium tuberculosis is reported to inhibit Th2-mediated
eosinophilia by inducing contra-acting Th1 cells.18,19
Transforming growth factor (TGF)-b , with properties that
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inhibit a wide variety of inflammatory responses, could be
another candidate for ameliorating immune-mediated
disorders.20 The TGF-b -secreting CD4+ T cells are
induced by antigen feeding and in turn inhibit tracheal
eosinophilia.21 Similar TGF-b- secreting CD4+ T cells
have been found to be induced in response to high doses
of antigens in the trachea and the inhibition of tracheal
eosinophils occurrs in parallel with the inhibition of the 
IL-4-producing ability of mediastinal lymph node (LN) 
T cells.22
Some pro-inflammatory cytokines are known to 
potentiate eosinophilic inflammation. Granulocyte–
macrophage colony stimulating factor (GM-CSF) has
pronounced effects on eosinophilia by extending the sur-
vival and promoting maturation and activation.23–25
Interleukin (IL)-1 enhances eosinophil migration and infil-
tration by enhancing adhesion molecules on endothelial
cells or by the secretion of other cytokines.26–34
We have reported previously that high doses of antigen
in the trachea induce Th2 cell tolerance, which we
referred to as tracheal high-dose tolerance.22 The toler-
ance was found to be mediated by TGF-b secreted from
CD4+ T cells, while the roles of antigen-presenting cells
(APC) and pro-inflammatory cytokines remained unex-
plored. In the present study, we examined the mechanisms
of tracheal high-dose tolerance with regard to accessory
cell functions and the effects of pro-inflammatory
cytokines on the tolerance. We found that, as well as the
induction of TGF-b -secreting CD4+ T cells, the high-dose
tolerance in the trachea includes an impairment of acces-
sory cell functions that support IL-4 production from 
T cells, which was reversed by GM-CSF.
METHODS
Animals and immunization
BALB/c mice were bred in our animal facility and were
used at 5–10 weeks of age. These animals were primed
intraperitoneally with 10 m g ovalbumin (OVA; Sigma
Chemical Co., St Louis, MO, USA) precipitated with 
4 mg aluminum hydroxide (alum) in 200 m L phosphate-
buffered saline three times at weekly intervals. Seven days
after the last immunization, the mice were challenged
with intratracheally administered OVA, as described later.
BALB/c mice transgenic (tg) for T cell receptor (TCR) 
specific for OVA323–339 and I-Ad35 were primed intraperi-
toneally with 10 m g OVA in alum and the spleen was
used as a source of CD4+ T cells after 7 days.
Antigen-induced eosinophilic infiltration in the
trachea
The methods have been detailed previously.21 In brief,
1 week after the last intraperitoneal immunization with
OVA/alum, sensitized mice were lightly anesthetized with
pentobarbital (Abbott Laboratories, North Chicago, IL,
USA), and graded doses of OVA were instilled directly into
the surgically exposed trachea. After 2 days, the excised
trachea was fixed in 10% formalin and frozen in optimal
cutting temperature (OCT) compound (Miles Laboratories,
Naperville, IL, USA). Cryosections (7 m m thick) from the
frozen tissue were stained with Diff-Quik (International
Reagents Corporation, Kobe, Japan). The numbers of
eosinophils infiltrating into the submucosal tissue of the
trachea were determined by light microscopy. The peri-
meter of the basement membrane of the trachea was
measured with a microcomputer imaging device (MCID)
image analyzer (Imaging Research Inc., St Catherines,
Ontario, Canada). For every trachea, six to eight sections
were used for counting, each separated from the adjacent
one by over 70 m m. Results were converted to the number
of eosinophils per 1 mm section of basement membrane.
Each point represents the mean ± SEM for four to seven
mice from one experiment. Results are representative of
two or three independent experiments.
In vitro culture and assay for IL-4 and IL-5
BALB/c mice primed intraperitoneally with OVA/alum
three times were challenged intratracheally with 10 m g
OVA or 500 m g OVA either alone or with 10 ng GM-CSF
(R&D Systems, Minneapolis, MN, USA) or IL-1b (R&D
systems). After 7 days, 1 · 105 mediastinal LN cells were
cultured with 100 m g/mL OVA in 96-well plates for
2 days. Otherwise, Ia+ cells as antigen-presenting cells
(2 · 104/well) and CD4+ T cells (2 · 104/well) were
cocultured under the same culture conditions. Ia+ cells
were prepared by means of anti-Ia beads (Miltenyi
Biotec, Gladbach, Germany) and a magnetic activated
cell sorter (MACS; Miltenyi Biotec GmbH) from medi-
astinal LN of BALB/c mice that received an intratracheal
administration of 10 m g OVA or 500 m g OVA either
alone or with 10 ng GM-CSF 7 days before. The CD4+
T cells were prepared from spleen of anti-OVA tg mice
primed with OVA/alum 7 days before using anti-CD4
beads and MACS. The concentrations of IL-4 and IL-5 in
the culture supernatants were determined by enzyme-
linked immunosorbent assay (ELISA) with paired anti-IL-4
and -IL-5 monoclonal antibodies, respectively (Pharmingen,
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San Diego, CA, USA) and tetramethylbenzidine reagent
(Kierkegaard and Perry, Gaithersburg, MD, USA) accord-
ing to the manufacturer’s recommendations. Standard
recombinant mouse IL-4 and IL-5 was purchased from
Genzyme (Genzyme Co., Cambridge, MA, USA). The
purity of Ia+ or CD4+ cells was always > 95% by reanaly-
ses. The detection level of IL-4 or IL-5 was > 20 pg/mL.
Assay of transforming growth factor-b
Anti-ovalbumin tg mice were treated intratracheally with
10 m g OVA or 500 m g OVA either alone or with 10 ng
GM-CSF. After 7 days, 1 · 105 mediastinal LN cells were
cultured with or without 100 m g/mL OVA in 96-well
round-bottomed plates for 3 days. Levels of TGF-b were
determined as described previously.21 In brief, culture
supernatants were applied to 96-well microtiter plates
coated with chicken antihuman TGF-b 1 antibody
(5 m g/mL; R&D Systems). Bound TGF-b was detected by
monoclonal anti-TGF-b (1 m g/mL) (Genzyme), followed
by peroxidase-labeled goat antimouse IgG (1 m g/mL;
Kierkegaard and Perry) and tetramethylbenzidine reagent
(Kierkegaard and Perry). Optical densities were deter-
mined at 450 nm and converted to concentrations
(ng/mL) according to the standard curve obtained with
titrated concentrations of human recombinant TGF-b 1
(R&D Systems). The minimum detection level of TGF-b
was > 50 pg/mL.
Statistics
Statistical significance was determined by Student’s t-test.
RESULTS
Granulocyte–macrophage colony stimulating
factor and IL-1b augmented tracheal
eosinophilias induced by high, but not low,
doses of antigen
We have previously shown that tracheal eosinophilia
evoked by OVA is regulated in an antigen dose-dependent
manner; 10 m g OVA in the trachea elicits the maximal
eosinophilic responses, while higher or lower doses of
OVA induces reduced levels of eosinophilia (Fig. 1).21
We examined whether the lack of optimal eosinophilic
responses induced by high or low doses of OVA could 
be reversed by pro-inflammatory cytokines. In our pre-
liminary experiments with graded doses of GM-CSF or
IL-1, 10 ng of cytokines showed maximal effects (data 
not shown). When 10 ng GM-CSF was given intra-
tracheally together with graded doses of OVA, it exerted
no enhancing effects on the eosinophilia induced by 
low or optimal doses of OVA (approximately 10 m g; 
Fig. 1a). In contrast, GM-CSF reversed the low eosino-
philic responses evoked by higher doses of OVA to 
levels comparable to those induced by optimal antigen
doses. Similar observations were obtained when another 
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Fig. 1 Granulocyte–macrophage colony stimulating factor (GM-CSF)- and interleukin (IL)-1b -augmented tracheal eosinophilia
induced by high, but not low, doses of antigen. BALB/c mice immunized intraperitoneally with ovalbumin (OVA)/
alum three times were given an intratracheal administration of titrated doses of OVA either alone (r) or with 10 ng GM-CSF (j)
or 10 ng IL-1 b (s). The numbers of eosinophils infiltrating in the trachea were determined as described in Methods. Each point is
the mean ± SEM for four to seven mice from one experiment. Results are representative of two or three independent 
experiments.
pro-inflammatory cytokine, IL-1b , was given; eosino-
philia elicited by only high doses of OVA was increased
by IL-1b (Fig. 1b). These results indicate that the impair-
ment in eosinophilia induced by high, but not low, doses
of OVA could be circumvented by the pro-inflammatory
cytokines.
Granulocyte–macrophage colony stimulating
factor, but not IL-1b , restored IL-4 production
by mediastinal LN cells from high-dose toler-
ant mice
We have reported previously that the low levels of tracheal
eosinophilia elicited by a high dose of OVA in the trachea
are attributable to the tolerance of CD4+ Th2 cells, which
we referred to as tracheal high-dose tolerance.22
Because restoration of the eosinophilic responses by pro-
inflammatory cytokines may reflect the up-regulation of
Th2 cells in regional LN cells, we examined whether
simultaneous intratracheal instillation of GM-CSF or 
IL-1 b with high doses of OVA increased the IL-4 produc-
tion from mediastinal LN cells. Interleukin-4 production
from mediastinal LN cells from mice receiving high doses
of antigen was impaired in comparison to production in
mice receiving optimal doses of OVA (Fig. 2a,b;
P < 0.0001). The down-regulated IL-4 production from
high-dose tolerant mice was not reversed by intratracheal
instillation of IL-1b (Fig. 2b), whereas another pro-
inflammatory cytokine, GM-CSF, augmented the IL-4
production to levels comparable to those produced by
the optimal antigen doses (Fig. 2a). These results indicate
that two pro-inflammatory cytokines up-regulate the
eosinophilia induced by high doses of antigen through
distinct mechanisms; GM-CSF enhanced eosinophilia by
restoring the impaired Th2 function, while IL-1b did so 
by other mechanisms.
Restoration of impaired APC function from
high-dose tolerant mice by GM-CSF
We have reported that tracheal high-dose tolerance is
due to the induction of TGF-b -secreting CD4+ T cells,
which inhibit Th2 cells.22 Here, we tried to determine
whether the impaired ability of APC to activate Th2 cells
was another possible mechanism of high-dose tolerance
and, if so, whether the restoration of eosinophilia by 
GM-CSF was in parallel with the improved ability of APC.
CD4+ T cells prepared from OVA/alum-primed anti-
OVA TCR tg mice were cocultured with Ia+ cells of
mediastinal LN, and the levels of IL-4 and IL-5 in culture
supernatants were determined by ELISA. In comparison
with Ia+ cells from animals receiving optimal doses of
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Fig. 2 Granulocyte–macrophage colony stimulating factor (GM-CSF), but not interleukin (IL)-1b , restored IL-4 production by
mediastinal lymph node (LN) cells from high-dose tolerant mice. BALB/c mice were primed intraperitoneally with ovalbumin
(OVA)/alum three times and then challenged intratracheally with 10 m g OVA, or 500 m g OVA either alone or with 1 ng GM-CSF (a)
or IL-1b (b). After 7 days, mediastinal LN cells were cultured in vitro with 100 m g/mL OVA for 48 h. Culture supernatants were assayed
for IL-4 by enzyme-linked immunosorbent assay. The failure of mediastinal LN cells from high-dose tolerant mice to produce IL-4 was
restored by intratracheal administration of GM-CSF (a), but not by IL-1b (b). The results of in vitro cultures are given as the mean
± SEM of four wells. The data shown are representative of two independent experiments. (*P < 0.002; **P < 0.0001).
OVA, those receiving high doses of OVA had an
impaired ability to stimulate CD4 T cells to produce IL-4
(Fig. 3a, middle bar; P < 0.002) or IL-5 (Fig. 3b, middle
bar; P < 0.002). Interestingly, the deteriorated ability of
APC was overcome by GM-CSF; when GM-CSF was
concomitantly given intratracheally together with high
doses of OVA, the impaired function of APC from medi-
astinal LN was fully restored to the optimal levels, as
judged by the ability to induce IL-4 (Fig. 3a, right bar) and
IL-5 (Fig. 3b, right bar) secretion from T cells. These
results revealed a strict relationship between the ability of
APC to induce Th2 cytokine secretion and the extent of
tracheal eosinophilia and showed that GM-CSF, which
restored eosinophilia by high doses of OVA, also
empowered APC to stimulate Th2 cells.
Inhibition of TGF-b production from high-dose
tolerant LN cells
We examined effects of GM-CSF on TGF-b production
from high-dose tolerant LN cells. As we have described
previously,22 the mediastinal LN cells from anti-OVA 
TCR tg mice receiving high doses of OVA (500 m g)
produce TGF- b in response to in vitro antigen challenge
(P < 0.05), whereas the concomitant intratracheal
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Fig. 3 Restoration of impaired antigen-presenting cell function from high-dose tolerant mice by granulocyte–macrophage colony
stimulating factor (GM-CSF). BALB/c mice were instilled intratracheally with 10 m g or 500 m g ovalbumin (OVA), or 500 m g OVA plus
GM-CSF. After 7 days, Ia+ cells were separated from their mediastinal lymph nodes. The mitomycin C (MMC)-treated Ia+ cells were
cultured with 100 m g/mL OVA and CD4+ splenic T cells from anti-OVA T cell receptor transgenic mice that had been primed with
OVA/alum 7 days before. After 2 days, culture supernatants were assayed for IL-4 (a) and IL-5 (b) by enzyme-linked immunosorbent
assay. Low efficacy of the Ia+ cells from high-dose tolerant mice to support T helper cell 2 cytokine production was restored by intra-
tracheal administration of GM-CSF. The results of in vitro cultures were given as the mean ± SEM of four wells. The data shown are
representative of two independent experiments. *P < 0.05, **P < 0.01, ***P < 0.002.
Fig. 4 Inhibition of transforming growth factor (TGF)-b pro-
duction from high-dose tolerant lymph node (LN) cells. Anti-
ovalbumin (OVA) transgenic mice were treated intratracheally
with 10 m g OVA, or 500 m g OVA either alone or with 10 ng
granulocyte–macrophage colony stimulating factor (GM-CSF).
After 7 days, 1 · 105 mediastinal LN cells were cultured with
or without 100 m g/mL OVA in 96-well round-bottomed plates
for 3 days. Levels of TGF-b were determined by enzyme-linked
immunosorbent assay. The results of in vitro cultures were
given as the mean ± SEM of four to six wells after TGF-b levels
secreted in an antigen-non-specific fashion were subtracted.
The data shown are representative of three independent exper-
iments. *P < 0.01; and **P < 0.0001.
treatment with OVA and GM-CSF abolishes production
of TGF-b (Fig. 4). Thus, the restoration of the Th2 
function was in parallel with the abolition of TGF-b
production.
DISCUSSION
The down-regulation of harmful immune responses to
inhaled antigens is a possible approach to immunother-
apy for bronchial asthma. Two components that play
crucial roles in the pathogenesis of bronchial asthma are
elevated IgE levels and eosinophilic inflammation in the
airways, both of which are orchestrated by cytokines
elaborated by Th2 cells.3–9 Selective abrogation of the
Th2 cell-mediated responses specific for allergen, with
sparing of other immune functions, averts such adverse
effects as the deterioration of host defenses, which is
inevitable when antigen-non-specific immunosuppres-
sants are used.
We have demonstrated previously that high doses of
antigen in the trachea inhibit eosinophilic inflammation
by down-regulating the IL-4 production of CD4+ T
cells.22 The impairment of IL-4 production is mediated by
TGF- b secreted from another CD4+ T cell subset.22 In the
present study, we examined the mechanisms of the 
tracheal high-dose tolerance with regard to accessory
cell functions and the effects of pro-inflammatory
cytokines on this tolerance. The concurrent intratracheal
instillation of GM-CSF or IL-1b with high doses of
antigen restored the tracheal eosinophilia (Fig. 1), while
augmentation of eosinophilia by GM-CSF, but not by 
IL-1 b, was accompanied by a parallel increase in IL-4
production in CD4 T cells from the mediastinal lymph
nodes (Fig. 2). The prevention of tolerance reflected the
empowerment of APC by GM-CSF (Fig. 3). Thus, expo-
sure of the airway to high doses of antigen led to the
inhibition of the antigen-presenting ability, with conse-
quent failure of T cells to produce IL-4 and IL-5, and
scant eosinophilic inflammation.
Granulocyte–macrophage colony stimulating factor
and IL-1 b enhanced the tracheal eosinophilia induced by
high doses of OVA (Fig. 1). Both of these cytokines have
stimulatory effects on eosinophils. Interleukin-1 facilitates
eosinophil adhesion to and transmigration through
endothelial cells by up-regulating adhesion mole-
cules.26–30 Interleukin-1b also promotes eosinophil
recruitment by inducing the secretion from endothelial
cells of other cytokines, including GM-CSF, eotaxin or
monocyte chemoattractant protein (MCP)-4.31–33 Direct
injection of IL-1b has been reported to induce eosinophil
accumulation in vivo.34 Granulocyte–macrophage colony
stimulating factor has other pronounced effects on
eosinophils by extending their survival and promoting
their maturation and activation.23–25 Additional novel
mechanisms were noted for GM-CSF in the present
experiments. Granulocyte–macrophage colony stimulat-
ing factor, but not IL-1b, restored the function of
IL-4-producing T cells. (Fig. 2). The prevention of toler-
ance was ascribed to the up-regulation of APC functions,
which otherwise remain down-regulated by high doses of
antigen (Fig. 3). Roles of IL-1b in the prevention of toler-
ance36–39 or enhancement of dendritic cell function40–42
have been reported, although IL-1b neither prevented the
tolerance nor restored the APC functions in the present
study. These results imply that GM-CSF plays a critical
role in the induction and prevention of tracheal high-
dose tolerance, which is not compensated by IL-1b .
Granulocyte–macrophage colony stimulating factor, in
addition to its effects on eosinophils, plays an essential
role in the activation and maturation of antigen-presenting
cells or dendritic cells.43,44 In peripheral tissues, immature
dendritic cells, as sentinel APC, capture antigens with
poor antigen presentation, while they acquire a potent
capability to present antigens to T cells in lymphoid
tissues.45–50 Immature dendritic cells, such as skin Langer-
hans cells or airway dendritic cells, are deficient in the
expression of costimulatory molecules.51–54 Stimulation of
T cells by such costimulatory molecule-deficient APC results
in the unresponsiveness of T cells, namely anergy.55,56 The
gain of stimulatory and the loss of tolerogenic properties
of APC is accompanied by the up-regulation of costimula-
tory molecules by cytokines such as GM-CSF.43,53 These
observations are well in accord with those of ours in which
GM-CSF broke the tolerance induction. Our experiments
demonstrated the novel finding that enhancement of APC
with GM-CSF blocked the suppressive effects of TGF-b -
secreting T cells on Th2-mediated inflammation. The
inhibitory effects of the TGF-b -secreting T cells were no
longer observed after restoration of the APC function by
addition of GM-CSF (Fig. 3). We did not clarify the precise
mechanisms underlying the reversal of the inhibitory T
cells. One possible mechanism is that APC that remained
unactivated, due to a lack of GM-CSF, may have prefer-
entially induced TGF-b -secreting T cells at the expense of
IL-4- and IL-5-producing cells. Another possibility is that
activated APC stimulated IL-4- and IL-5-producing T cells
more efficiently than TGF-b -producing T cells and the
former outnumber the latter, with a resultant restoration of
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IL-4 production. Regardless of the underlying mechan-
isms, we found that APC that were not activated in a
proper manner could down-regulate the immune
responses by inducing suppressor T cells in addition to
inducing T cell anergy.
In summary, we report in the present paper that the
impaired function of APC is another cause of tracheal
high-dose tolerance. We believe that this is the first report
that reveals the prevention of tolerance by the empower-
ment of APC, which otherwise induce suppressor T cells.
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